Chemotherapy with EGFR-tyrosine kinase inhibitor (EGFR-TKI) or chemotherapy alone in elderly patients with advanced NSCLC with acquired resistance to EGFR-TKI (NEJ017)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000008364
- Lead Sponsor
- orth East Japan Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1)Patients with severe drug allergy 2)Patients with active infection 3)Patients who uses steroids or immunosuppressant drugs 4)Patients with uncontrollable disease 5)Patients with interstitial pneumonia or pulmonary fibrosis on chest CT 6)Patients with massive pleural effusion, ascites, pericardial effusion (drainage or pleurodesis with OK432 or minocylcine are permissive.) 7)Patients who received surgery within 3 weeks or radiotherapy within 2 weeks of registration 8)History of active double cancer within 5 years 9)Patients who have the possibility of pregnancy or in lactation period 10)Patients with symptomatic brain metastases 11)HBs antigen positive 12)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression-free survival
- Secondary Outcome Measures
Name Time Method